Nebivolol Accord Healthcare (Nebivolol)

Nebivolol selectively blocks β1‑adrenergic receptors on cardiac cells, decreasing heart‑rate and contractile force. At the same time it stimulates endothelial nitric‑oxide synthase, which raises nitric‑oxide levels and causes vasodilation. The combined effect reduces peripheral resistance and blood pressure while supporting better cardiac efficiency.

The appropriate nebivolol dose is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and any co‑existing health issues. Dosage may be adjusted during treatment, and patients should follow the exact regimen provided by their healthcare professional.

Safety data for nebivolol in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will evaluate each case individually before prescribing.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nebivolol is a β1‑selective blocker with additional nitric‑oxide‑mediated vasodilatory properties, which can provide better tolerability regarding metabolic effects and fewer central nervous system symptoms compared with non‑selective beta‑blockers. Its dual action may result in effective blood‑pressure control with a lower incidence of certain side effects.

Nebivolol tablets should be stored at ambient temperature, preferably below 25 °C, in their original packaging to protect them from moisture and light. Keep the product out of reach of children and do not store in humid or excessively hot environments.

Nebivolol is taken orally, usually once daily, with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include marked bradycardia, severe hypotension, and acute bronchospasm in patients with asthma or chronic obstructive pulmonary disease. Patients should be monitored for symptoms such as dizziness, fainting, or difficulty breathing, and medical attention should be sought promptly if these occur.

Nebivolol is contraindicated in individuals with known hypersensitivity to the drug, those experiencing severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and patients with uncompensated heart failure. It should also be used with caution in patients with severe liver or kidney impairment.